Edition:
United States

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

65.00USD
11:26am EDT
Change (% chg)

$-0.58 (-0.88%)
Prev Close
$65.58
Open
$65.50
Day's High
$65.52
Day's Low
$64.80
Volume
382,581
Avg. Vol
1,947,759
52-wk High
$68.12
52-wk Low
$55.10

Latest Key Developments (Source: Significant Developments)

Coherus Biosciences prevails in '135 IPR decision
Tuesday, 16 May 2017 07:29pm EDT 

May 16 (Reuters) - Coherus Biosciences Inc ::Coherus Biosciences prevails in '135 IPR decision.Coherus Biosciences - patent trial, appeal board of U.S. Patent And Trademark Office ruled in favor of review of Abbvie's U.S. patent 8,889,135.Coherus Biosciences-decision invalidates claims of patent that directed to method for treating rheumatoid arthritis by administering 40 MG of humira."Pleased that PTAB has decided to invalidate all claims of '135 patent".  Full Article

AbbVie CEO says the tax reform announced yesterday, is encouraging: Conf Call
Thursday, 27 Apr 2017 09:15am EDT 

April 27 (Reuters) - AbbVie Inc :AbbVie CEO: "In the U.S., Humira grew 22.8 percent, driven by robust underlying demand, including prescription volume growth of 12 percent".AbbVie continues to expect mid-single-digit operational sales Humira growth in 2017 internationally despite impact from rival drugs and indirect biosimilar competition.AbbVie says data readouts from 12 pivotal trials expected by the end of 2017: Conf Call.AbbVie CFO: "For U.S. Humira, we expect sales growth in the second quarter in the mid to high teens": Conf Call.AbbVie CFO: "For Imbruvica, we expect U.S. sales growth in the second quarter to approach 35 percent": Conf Call.AbbVie CFO: "With respect to the tax rate, future quarters should be modeled at above 19 percent": Conf Call.AbbVie CEO: Generally speaking, the tax reform announced yesterday, is encouraging: Conf Call.AbbVie CEO: Tax reform plan certainly will put us in a position where will be far more competitive to our foreign competitors: Conf Call.AbbVie CEO "if we were to get tax reform where we could get better access or more cost-effective access to our offshore cash, we're certainly going to be looking at ways to be able to appropriately deploy that cash".AbbVie CEO "returning cash to shareholders to reward them for their tremendous success that Humira has had and will continue to have going forward is a high priority for us".  Full Article

Abbvie Q1 adjusted earnings per share $1.28
Thursday, 27 Apr 2017 07:38am EDT 

April 27 (Reuters) - Abbvie Inc :Abbvie reports first-quarter 2017 financial results.Reaffirms fy 2017 gaap earnings per share view $4.55 to $4.65.Q1 adjusted earnings per share $1.28.Q1 gaap earnings per share $1.06.Reaffirms fy 2017 adjusted earnings per share view $5.44 to $5.54.Q1 revenue rose 10.1 percent to $6.538 billion.Q1 earnings per share view $1.26, revenue view $6.48 billion -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $5.49 -- Thomson Reuters I/B/E/S.Abbvie inc - qtrly total humira revenue $ 4,118 million versus. $ 3,577 million last year.  Full Article

Abbvie submits supplemental new drug application for ibrutinib
Tuesday, 4 Apr 2017 07:00am EDT 

Abbvie Inc - : Abbvie announces ibrutinib (imbruvica®) supplemental new drug application for previously treated chronic graft-versus-host-disease (cgvhd) accepted for review by U.S. FDA .Abbvie Inc says imbruvica is jointly developed and commercialized by Pharmacyclics Llc, an Abbvie company, and Janssen Biotech, inc.  Full Article

U.S. FDA approves addition of moderate to severe fingernail psoriasis data to Abbvie's humira
Thursday, 30 Mar 2017 07:00am EDT 

Abbvie Inc : U.S. FDA approves addition of moderate to severe fingernail psoriasis data to Abbvie's Humira (adalimumab) prescribing information . U.S. FDA approves addition of moderate to severe fingernail psoriasis data to Abbvie's Humira (adalimumab) prescribing information .Abbvie Inc - phase 3 data demonstrate improvement in moderate to severe fingernail psoriasis.  Full Article

Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067
Wednesday, 22 Mar 2017 02:31am EDT 

Galapagos NV : Initiates Phase 1 study with novel CF potentiator GLPG3067 . Triggers a $7.5 million milestone payment from AbbVie . Third potentiator in growing portfolio of cystic fibrosis drug candidates . Aim of the phase 1 study is to evaluate the safety, tolerability and pharmacokinetics of oral single and multiple ascending doses of GLPG0367 . Safety and tolerability of the combination of GLPG3067 and GLPG2222 will also be evaluated. ."we plan to initiate multiple studies within our cf portfolio in the course of this year, as we get closer to our goal of initiating a patient evaluation of a triple combination therapy by mid-2017." - CSO.  Full Article

Abbvie CEO Richard Gonzalez's FY 2016 total compensation was $21 mln
Monday, 20 Mar 2017 12:51pm EDT 

Abbvie Inc : CEO Richard Gonzalez's FY 2016 total compensation was $21.0 million versus $20.8 million in FY 2015 - sec filing . Abbvie inc - CFO William J. Chase's 2016 total compensation was $8.8 million versus $7.6 mln in 2015 - sec filing . EVP Laura Schumacher's FY 2016 total compensation $8.22 million versus $7.31 million in FY 2015 .Abbvie Inc - Chief Scientific Officer Michael E. Severino's 2016 total compensation was $7.2 million versus $6.6 million in 2015 - sec filing.  Full Article

Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir
Tuesday, 14 Mar 2017 08:00am EDT 

Abbvie Inc : Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir/Pibrentasvir (G/P) for the treatment of all major genotypes of chronic hepatitis c .Priority review follows EMA accelerated assessment and U.S. FDA priority review designations in December 2016 and January 2017 respectively.  Full Article

Abbvie sets quarterly cash dividend of $0.64 per share
Thursday, 16 Feb 2017 12:41pm EST 

AbbVie Inc : Maintains quarterly dividend .Sets quarterly cash dividend of $0.64 per share.  Full Article

Neurocrine Biosciences reports Q4 loss per share $0.51
Tuesday, 14 Feb 2017 04:24pm EST 

Neurocrine Biosciences Inc : Neurocrine Biosciences reports year-end 2016 results and provides investor update for 2017 . Q4 loss per share $0.51 . Q4 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S . Neurocrine Biosciences Inc- Revenues from milestones under abbvie agreement for 2017 are expected to be $30 million .Neurocrine Biosciences-2017 ongoing operating expenses should approximate $230 million to $240 million, exclusive of $30 million up-front fee for in-licensing opicapone.  Full Article

More From Around the Web

Photo

Wall Street tumbles as reform hopes fade with Trump crisis

The S&P 500 and the Dow notched their biggest one-day fall since Sept. 9 as investor hopes for tax cuts and other pro-business policies faded after reports that U.S. President Donald Trump tried to interfere with a federal investigation set off alarm bells on Wall Street. | Video